Neurocrine Biosciences (NBIX) – Trader Talk
-
Needham & Company Reiterates Neurocrine (NBIX) at Hold, "Love Execution on Ingrezza" but Cautious on Future Pipeline Readouts
-
Neurocrine (NBIX) Maintained at Underperform by BMO, PT Hiked to $74, Analyst Sees Challenging Q1
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to NBIX Stock Lookup